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Abstract
Background: Primary care providers (PCPs) are typically the first to screen and evaluate patients for neurocognitive
disorders (NCDs), including mild cognitive impairment and dementia. However, data on PCP attitudes and evaluation
and management practices are sparse. Our objective was to quantify perspectives and behaviors of PCPs and
neurologists with respect to NCD evaluation and management.
Methods: A cross-sectional survey with 150 PCPs and 50 neurologists in the United States who evaluated
more than 10 patients over age 55 per month. The 51-item survey assessed clinical practice characteristics,
and confidence, perceived barriers, and typical practices when diagnosing and managing patients with NCDs.
Results: PCPs and neurologists reported similar confidence and approaches to general medical care and
laboratory testing. Though over half of PCPs performed cognitive screening or referred patients for cognitive
testing in over 50% of their patients, only 20% reported high confidence in interpreting results of cognitive
tests. PCPs were more likely to order CT scans than MRIs, and only 14% of PCPs reported high confidence
interpreting brain imaging findings, compared to 70% of specialists. Only 21% of PCPs were highly confident
that they correctly recognized when a patient had an NCD, and only 13% were highly confident in making a
specific NCD diagnosis (compared to 72 and 44% for neurologists, both p < 0.001). A quarter of all providers
identified lack of familiarity with diagnostic criteria for NCD syndromes as a barrier to clinical practice.
Conclusions: This study demonstrates how PCPs approach diagnosis and management of patients with NCDs,
and identified areas for improvement in regards to cognitive testing and neuroimaging. This study also
identified all providers’ lack of familiarity with published diagnostic criteria for NCD syndromes. These findings may
inform the development of new policies and interventions to help providers improve the efficacy of their decision
processes and deliver better quality care to patients with NCDs.
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Background
In the United States, primary care providers (PCPs) are
typically the first to screen and evaluate patients with
neurocognitive disorders (NCDs) such as mild cognitive
impairment and dementia. Currently, in the primary care
setting, as many as two-thirds of people with dementia
may be misdiagnosed (i.e., the NCD syndrome and
neurologic etiology are misidentified), and there is often
a significant delay between symptom onset and diagnosis
[1–5]. Accurate diagnostic classification of an NCD de-
termines prognosis and symptomatic treatment, and is
necessary to identify the 2% of NCD cases with a revers-
ible underlying condition [2, 6]. Accurate and early diag-
nosis can also enable patients and families to make
important medical, legal, and financial decisions for the
future, develop safety measures in the home, participate
in clinical trials, and set goals for how to live with the
disease [7–10]. Additionally, accurate diagnosis can help
providers and patients work together to make lifestyle
modifications, such as diet, exercise, and medications, in
order to best manage symptoms [11–13].
PCPs have identified systems- and health service-level
barriers to the assessment, diagnosis, and management
of their patients with NCDs. These barriers include lack
of technological, financial, and human resources, as well
as inadequate time and expertise to educate patients and
families after a diagnosis of dementia [4, 14, 15]. PCPs
report difficulty addressing NCD symptoms in the con-
text of common comorbidities such as cardiovascular
disease [6], and both PCPs and patients commonly re-
port trouble accessing specialists [15]. In fact, more than
half of patients referred to an NCD specialist following a
positive screen in the primary care setting do not obtain
further evaluation [16, 17]. PCPs, not specialists, carry
the principal responsibility of diagnosing and caring for
the majority of patients with NCDs, yet experience
major barriers to managing patients [17, 18] Further-
more, there is disagreement about what constitutes an
appropriate evaluation and which screening tools best fit
a patient’s characteristics and presenting symptoms.
While some efforts have been made to create consensus
protocols in this area, particularly for specific syn-
dromes such as Alzheimer’s disease (AD), no compre-
hensive guidelines for NCD evaluation or choice of tools
have been widely adopted [19, 20]. For example, while
there is broad support among neurologists for using
MRI rather than CT for brain imaging, the field has
never formalized this standard of care21, 22.
In this study, we surveyed a national sample of PCPs
in order to characterize their experiences and practices
with respect to NCD evaluation and management. To
better identify how PCP behaviors and attitudes differ
from those of specialists trained in NCD diagnosis and
care, a sample of neurologists was also surveyed. Given
the systems-level barriers in primary care and the uncer-
tainty around standards of care, our goal in this paper is
to provide insights into provider attitudes and behaviors
as a way to understand where guidelines may be most
useful, and to identify specific areas to focus training
and policy interventions. A clearer understanding of
PCP attitudes, practices, and perceived barriers may
guide efforts to better support their ability to provide
quality care for the growing population of patients with
NCDs and to improve health services for people with
suspected NCDs.
Methods
Participants
Eligible participants were contacted via email invitation
from a proprietary database of 5 million panelists. PCPs
and neurology specialists who accepted the invitation
were provided a link to a web page describing the pro-
ject, anonymity policy, compensation appropriate based
on specialty (between $23–$42 per survey), and partici-
pation requirements. Those who agreed to participate
provided written consent in a form provided through
the survey link and answered eligibility screening ques-
tions confirming that they 1) were a neurologist or PCP,
and 2) saw more than 10 patients per month over the
age of 55. The first 100 eligible PCP and the first 50
neurologist respondents were enrolled and completed
the survey. The study was approved by the Institutional
Review Board at the University of California, San Fran-
cisco (UCSF).
Survey
The survey was designed by academic clinical re-
searchers at UCSF specializing in dementia diagnosis
and care, and was constructed to reflect domains from a
behavior change model for implementation research
called the Behavior Change Wheel Framework (BCW)
[23]. The BCW is a theory-driven approach that uses a
synthesis of 19 behavior change models. The BCW
framework enabled us to understand provider behaviors,
which can ultimately lead to the development of strat-
egies for improvement and intervention targets that will
most likely bring about clinic- and provider-level change
[24]. Specifically, the survey measured providers' confi-
dence, satisfaction, attitudes, and behaviors towards per-
forming activities related to the diagnosis and
management of NCDs, as well as their clinical practice
characteristics (see Additional file 1). Providers responded
to questions about the frequency with which they engage
in specific activities related to the assessment, diagnosis,
and care of their patients with NCDs, the usefulness of
specific tools and tests (cognitive assessments, labs, im-
aging, screens), and what tools and knowledge would im-
prove their ability to assess, correctly diagnose, and
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provide high-quality ongoing care for all common NCDs.
Information on practice setting and typical patient demo-
graphics was also collected.
Statistical analysis
Providers’ demographic data and outcome measures were
summarized with descriptive statistics. Mean differences
between PCPs and neurologists on stratified confidence
rankings were tested using Wilcoxon Rank Sum Tests,
accepting significance at p < 0.05 (IBM Corporation, SPSS
Version 24, Armonk, NY).
Results
Provider and patient characteristics
Provider and practice characteristics
Table 1 shows the stratification of PCPs and neurol-
ogists according to their practice setting. The ma-
jority of PCPs surveyed worked in private group
practices, private individual practices, or academic
medical centers. Neurologists predominantly worked
in private group practices or in academic medical
centers.
Typical patient characteristics
Table 2 shows that both PCPs and neurologists treated
an average of about 150 patients over age 55 per month,
about a quarter of whom were insured by Medicaid.
Neurologists diagnosed mild cognitive impairment (19.5
new cases per month, SD = 18.6) and dementia (17.7
new cases per month, SD = 18.2) significantly more often
than did PCPs (11.7 ± 17.4 and 9.8 ± 15.4, respectively).
Neurologists reported managing care for an average of
85 NCD patients per month, with 57% of their patients
over age 55; in contrast, PCPs managed an average of 51
NCD patients per month, with about one third of their
patients over age 55.
Provider confidence
Confidence in providing general medical care
PCPs and neurologists reported similar levels of confi-
dence (no significant difference) in managing the general
medical care of NCD patients, with between 46 and 64%
of providers reporting high confidence levels.
Confidence recognizing and diagnosing NCDs
PCPs reported significantly lower confidence levels than
neurologists in both the ability to correctly recognize
that an NCD is present, and the ability to distinguish
among specific NCD syndromes (progressive supra-
nuclear palsy, behavioral variant frontotemporal demen-
tia, etc.) (p < 0.001). Only 21% of PCPs reported high
confidence levels in their ability to correctly recognize
when a patient had an NCD (mean 4.3, SD 1.3 on a
Likert scale of 7, with 1 as low and 7 as high), and 13%
reported high confidence levels in providing a specific
NCD diagnosis (mean 3.4, SD 1.6), compared to 72%
(mean 5.5, SD 1.4) and 44% (mean 5.0, SD 1.4) respect-
ively for neurologists.
Typical PCP practices and perceived barriers
Referrals
Table 3 shows that PCPs referred a large percentage of
patients with suspected NCDs to specialists. Fifty-four
percent of PCPs referred more than half of their patients
with suspected NCDs to a neurologist or other specialist
for a dementia evaluation, with no PCPs reporting that
they elected to do the workup in-house with 100% of
patients. Sixty-six percent of PCPs referred more than
half of their patients with suspected NCDs for
Table 1 Characteristics of the respondents surveyed (N = 150)
Survey Question PCPs (n = 100) Neurologists (n = 50)
Number % Number %
Practice Settinga,b
Academic 15 13.8 20 36.4
Accountable Care Organization 5 4.6 1 1.8
Community Health Center 9 8.3 5 9.1
Federally qualified health care center 6 5.5 1 1.8
HMO 4 3.7 1 1.8
Private Individual Practice 19 17.4 4 7.3
Private Group Practice 45 41.3 23 41.8
Other 6 5.5 0 0
Years in practice post–residency, mean (SD) 18.9 (10.4) – 14.7 (9.0) –
Providers who use electronic medical records 79 79 43 86
a The denominator for percentage calculations is 109, reflecting multiple practice settings for 6 clinicians
b The denominator for percentage calculations is 55, reflecting multiple practice settings for 2 clinicians
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neuropsychological testing with a specialist. Only 1% of
PCPs reporting never referring patients to neuro-
psychological testing.
Assessment and diagnostic testing
Forty-three percent of PCPs reported that with more
than half of their patients with suspected neurocognitive
impairment, they do not utilize any standardized diag-
nostic tools such as cognitive testing or imaging, and ra-
ther rely on evaluating solely by history and examination
(compared to 42% of neurologists) (Table 3).
Laboratory testing for reversible causes of dementia
Eighty-four percent of PCPs indicated that they order
lab panels for common reversible causes of cognitive im-
pairment such as B12 and thyroid stimulating hormone
in more than half of patients suspected to have an NCD
(compared to 86% of neurologists).
Depression screens
PCPs were more likely than neurologists to administer
depression screens. Sixty-two percent of PCPs reported
administering a standardized depression screen to over
half of their patients with cognitive concerns, compared
to 48% of neurologists.
Cognitive assessments
Fifty-percent of PCPs reported that they, or their staff,
administered a standardized cognitive screening test
(e.g., the Mini-mental State Exam [MMSE] or the
Montreal Cognitive Assessment [MOCA]) to over half
of their patients with cognitive concerns, compared to
66% of neurologists. Fifty-three percent of PCPs re-
ported administering the test themselves, while 15% gave
the task to a nurse, and 17% assigned the task to a physi-
cian’s assistant or other medical staff member. Thirty-
five percent of PCPs found standardized cognitive
screens highly useful for identifying whether a patient
had an NCD; only 4% reported that these screens would
not be of value to them.
Twenty percent of PCPs were highly confident in
interpreting cognitive testing results, while 13% had low
confidence. In comparison, 68% of neurologists were
highly confident in interpreting cognitive testing results,
while none reported low confidence.
When asked to identify reasons they might choose
not to conduct or order cognitive testing, 45% of
PCPs believed cognitive impairment could be ad-
equately assessed through the clinical interview and
observation, without the need for standardized cogni-
tive assessment tools. Other barriers to performing
cognitive testing were identified much less frequently
by PCPs, including lack of access to neuropsycho-
logical testing (6.8%), financial expense (12.7%), and
lack of time (5.9%).
Imaging
Some of the largest practice discrepancies between PCPs
and neurologists occurred in the domain of brain
imaging (Fig. 1). Only 15% of PCPs found brain scans to
be highly useful in making a dementia diagnosis, as
compared to 40% of neurologists. Furthermore, only
14% of PCPs reported high confidence in interpreting
brain imaging findings, compared to 70% of neurologists.
While neurologists most frequently ordered structural
MRI (69%), only 34% of PCPs reported ordering
structural MRI (p < 0.05) and instead favored brain CT
(41%, compared to 27% of neurologists; p < 0.05). Both
PCPs (9%) and neurologists (13%) rarely ordered FDG
PET imaging.
When asked to identify particular barriers to use of
brain imaging, 24% of PCPs identified a lack of familiar-
ity interpreting MRI results as a barrier, compared to 3%
of neurologists. Additional barriers included the expense
of neuroimaging (19% of PCPs), the time it takes to ob-
tain neuroimaging (7% of PCPs), neuroimaging results
not changing diagnosis (15% of PCPs), and the value of
neuroimaging based on their interpretation of practice
guidelines (11% of PCPs).
Table 2 Providers’ reported patient characteristics
Survey Question PCPs (n = 100) Neurologists (n = 50)
Mean (SD) Median Mean (SD) Median p valuea
Patients treated per month, number 295.3 (179.1) 300 283.8 (157.6) 250 0.701
Patients treated per month > 55 years old, number 156.4 (113.8) 127.5 150.1 (105.7) 127.5 0.742
Patients insured by Medicaid, % 23.2 (22.2) 15.0 25.9 (23.0) 20.0 0.488
New cases of mild cognitive impairment diagnosed/month 11.7 (17.4) 5 19.5 (18.6) 14.5 0.012
New cases of dementia diagnosed/month 9.8 (15.4) 2.5 17.7 (18.2) 10 0.005
Number of patients currently managed for mild cognitive impairment 27.6 (27.8) 20 41.4 (30.5) 34.5 0.006
Number of patients currently managed for dementia 23.1 (26.4) 10 43.4 (30.8) 40 < 0.001
NS: Not significant
a type III sum of squares
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Beliefs about practice improvement
Thirty-one percent of PCPs reported that they would be
highly likely to treat more patients with NCDs rather than
referring them to specialists if decision support tools were
available in their practices (Fig. 2). Thirty-seven percent
reported they were highly likely to find decision support
helpful for guiding their choice of assessment tests for
NCDs. Forty percent of PCPs reported they were highly
likely to find decision support helpful for guiding the diag-
nostic decision process, and 37% reported they were
highly likely to find decision support helpful for guiding
their patient management and ongoing care.
Discussion
In this study we characterized current primary care
provider and neurologist practices in the United States
with respect to the assessment, diagnosis, and manage-
ment of patients with NCDs, and identified areas to
target for practice and policy improvement. There is a
great deal of uncertainty and disagreement around
guidelines for NCD evaluation and the best tools to
use. Our goal in this paper was to identify specific
areas, based on provider attitudes, behaviors, and prac-
tices, where it might be best to focus attention when
creating standardized guidelines, training, and policy
Table 3 Frequency of Provider Practices
Measure PCPs (n = 100) Neurologists (n = 50)
% %
Frequency in which provider or staff refers patients to a neurologist or other specialist for a dementia workup
Greater than 50% of patients with cognitive concerns 54 22
Less than or equal to 50% of patients with cognitive concerns 46 52
Never 0 26
Frequency in which provider or staff refers a patient with suspected neurocognitive disorders for neuropsychological testing with a specialist
Greater than 50% of patients with cognitive concerns 66 44
Less than or equal to 50% of patients with cognitive concerns 33 52
Never 1 4
Frequency with which provider or staff evaluates by other clinical methods (history and examination) but without standardized tools
Greater than 50% of patients with cognitive concerns 43 42
Less than or equal to 50% of patients with cognitive concerns 54 48
Never 3 10
Frequency in which laboratory panels for reversible causes of cognitive impairment (B12, TSH, etc.) are included if no prior lab work has been done
Greater than 50% of patients with cognitive concerns 84 86
Less than or equal to 50% of patients with cognitive concerns 12 14
Uses other providers’ data 3 0
Never 1 0
Frequency in which standardized depression screen is administered to patients
Greater than 50% of patients with cognitive concerns 62 48
Less than or equal to 50% of patients with cognitive concerns 33 42
Never 4 8
Frequency in which provider or staff administers a standardized cognitive screening test to patients with cognitive concerns
Greater than 50% of patients with cognitive concerns 50 66
Less than or equal to 50% of patients with cognitive concerns 41 28
Never 5 4
Who most often administers cognitive screening tests to patients?
PCP 53 60
RN or NP 15 10
PA or other medical staff member 17 12
Neuropsychologist 13 18
Other 2 0
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interventions for both primary care providers and for
neurologists.
Our most notable findings were the lack of confidence
and reported ability of PCPs to effectively implement
and interpret cognitive testing and neuroimaging for the
detection and diagnosis of NCDs. PCPs did report simi-
lar levels of frequency to that of specialists in ordering
laboratory testing and in their confidence managing the
general medical care of patients with NCDs. PCPs were
even more likely to order depression screens, an import-
ant part of the NCD evaluation [25, 26]. However, their
confidence and clinical practices diverged from special-
ists when performing other medical procedures that can
provide early and accurate diagnosis of NCDs. Fifty-four
Fig. 1 Frequency of ordering particular neuroimaging studies during dementia evaluation for patients with no prior imaging results
Fig. 2 PCP mean Likert scores rating the helpfulness of decision support tools in choosing assessment procedures, how to perform differential
diagnosis of neurocognitive disorder syndromes, and how to approach treatment and care of patients with different neurocognitive disorders
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percent of PCPs referred more than half of their patients
with suspected NCDs to specialists (neurologists or neu-
ropsychologists), rather than testing and diagnosing
themselves, despite the fact that half of those patients
are unlikely to actually follow through with that referral
and obtain additional care [16, 17].
PCPs are often the sole care providers for individuals
with NCDs, yet, as noted in other studies, frequently take
a reactive rather than proactive approach to dementia
diagnosis and care, and may underutilize available evalu-
ation and management tools [15]. Prior investigations
have found that primary care providers report issues of
time, difficulty accessing and communicating with special-
ists, low reimbursement, difficulty connecting with service
agencies, and lack of interdisciplinary teams as major bar-
riers to the diagnosis and management of dementia in
their practice settings [14, 15, 17, 27]. In our study PCPs
also reported issues with time, reimbursement, and mak-
ing referrals to specialists. However, our more compre-
hensive survey identified additional challenges for primary
care providers in regards to the NCD evaluation process,
including the use of cognitive testing, brain imaging, and
standardized diagnostic criteria. Our findings suggest that
the evaluation process is a domain where substantial
guideline, training, and policy improvements can be made.
Surprisingly, we also found fewer practice differences
between PCPs and neurologists in the areas of cognitive
testing, imaging, and familiarity with diagnostic criteria
than might be expected. For example, in the initial
evaluation of patients with cognitive concerns, 43% of
PCPs and 42% of neurologists reported that with more
than half of their patients with suspected neurocognitive
impairment they do not implement formal cognitive
testing with standard diagnostic tools. This finding raises
concerns for those who believe that a specialty evalu-
ation for a neurocognitive disorder should include cog-
nitive testing.
Bridging gaps in care: training and policy implications
While there is still considerable uncertainty around stan-
dards for syndrome-agnostic NCD evaluation, multiple
consensus guidelines recommend cognitive testing as an
integral part of all NCD evaluations [19, 20, 28–30]. Yet,
we found that 50% of PCPs used cognitive screens or
tests in only half of their patients with suspected NCDs,
and only 20% reported they had high confidence in their
ability to interpret cognitive testing results compared to
68% of specialists. The most common cognitive screen-
ing tools currently used in primary care environments
for the detection of cognitive symptoms are the MMSE
[31] and the Mini-Cog [14]. However, novel and vali-
dated cognitive assessment tools are rapidly proliferat-
ing, but are often unknown to PCPs [10]. These new
tools can evaluate multiple distinct cognitive domains
(e.g., distinguishing memory, executive, language, and
visuospatial problems) and are administered in the same
amount of time as older screens (i.e., 10 min or less
[10, 32–36]). PCPs may benefit from training around
how objective cognitive testing can enhance early detec-
tion of NCDs [2, 15, 37] above and beyond the clinical
interview. Knowledge of the distinct domain of a patient’s
cognitive deficits is required for the application of stand-
ard differential diagnostic criteria for many NCDs such as
the Alzheimer’s syndromes, all primary progressive apha-
sia syndromes, and most other neurodegenerative disease
syndromes [19, 20, 28–30, 38–41]. Many PCPs need sup-
port for recognizing how specific patterns of cognitive
performance correspond to distinct NCD syndromes,
which would improve their confidence in using cognitive
tests for diagnostic purposes. Furthermore, programs to
improve PCPs’ awareness of, and access to, the brief and
streamlined cognitive assessment tools that are currently
available may be needed. Bridging these important practice
gaps through new training initiatives, guidelines, and policy
changes around the diagnostic testing procedures will en-
able more PCPs to effectively administer and interpret cog-
nitive tests themselves, substantially reducing costly and
time-consuming referrals for specialized cognitive evalu-
ation. These changes have the potential to ensure greater
continuity of care for patients and their families.
Our study also showed underlying causes of practice
difficulties in the use of brain imaging by PCPs in evalu-
ating their patients with NCDs. The use of structural
MRI to diagnose NCDs is a common standard in neuro-
logic practice, and is a key element of differential diagnosis
among different NCD syndromes [21, 22, 28, 29, 38, 40–
46]. However, we found that PCPs were substantially less
likely than specialists to order an MRI when evaluating a
patient with an NCD (34% versus 69%). PCPs also reported
low confidence levels in interpreting brain imaging findings
(14% of PCPs reported high confidence compared to 70%
of specialists), which may explain why PCPs are less likely
to order MRIs. A discrepancy was also found between PCPs
and specialists in the type of brain imaging ordered, which
likely reveals important differences in their use of neuroim-
aging in NCD cases. During the NCD diagnostic process,
an early step is to rule out non-neurodegenerative neuro-
logic causes of neurocognitive symptoms, such as a brain
tumor or stroke [19, 39]. This can be done fairly effectively
with either CT or a more expensive structural MRI.
However, MRI additionally allows for the identification
of specific areas of focal degeneration [47], which is im-
portant not only to identify neurodegeneration, but also
to differentiate among NCD syndromes. Brain CT scans
are much less useful for this purpose [19, 28, 45]. Our
study shows that PCPs ordered more CT scans than
MRI scans for their NCD patients (41% CT versus 34%
MRI). This data suggests that PCPs may be ordering
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imaging to rule out non-neurodegenerative conditions,
but not to make a precise NCD diagnosis. To increase
the confidence and capacity to provide specific and ac-
curate diagnoses for their NCD patients, many PCPs
may need clear guidelines and training as to which neu-
roimaging modality to prescribe given a patient’s par-
ticular presentation, as well as support for identifying
the most typical patterns of regional atrophy that dis-
tinguish common NCD syndromes.
While it may be premature to expect many PCPs to
become proficient at reading brain MRI scans, radiolo-
gists may also help PCPs if guidelines required them to
provide more syndrome-specific diagnostic information
in their clinical reports for patients with suspected NCDs.
Automated volumetric analysis of MRI scans is routinely
performed in clinical research settings, but translating
these diagnostic analytics into clinical practice could
dramatically improve PCPs ability to effectively utilize
neuroimaging themselves. While there is some disagree-
ment in primary care about which imaging tests are ap-
propriate and which are extravagant [48], many
specialists consider neuroimaging the foundation for the
accurate differential diagnosis among NCD syndromes
[19, 28, 47, 49]. Neuroimaging results, in turn, shape the
course of subsequent patient care, including treatment
decisions, prognosis, predicting disease course, and care
planning.
Finally, our survey identified a general lack of familiar-
ity among all providers with published diagnostic criteria
for the various NCD syndromes. One-quarter of all pro-
viders stated that this lack of knowledge is a highly sig-
nificant barrier to their evaluation and management of
patients with NCDs. Clearly, training on existing diag-
nostic guidelines is needed to improve all providers’
knowledge and confidence around patient diagnosis. The
underlying causes for this lack of comfort and know-
ledge may be remedied by routine exposure to standard
diagnostic rules and decision support tools. If providers
are more familiar with diagnostic criteria, they will in
turn be more confident and effective in utilizing cogni-
tive testing, imaging, and other key elements in their
evaluations. This will lead to high quality prognostica-
tion and ongoing care for their patients with NCDs.
As of 2017, newly created Medicare billing codes in the
United States have been established to allow providers
more time with patients, and to provide better reimburse-
ment when providers engage in comprehensive neurocog-
nitive evaluation and management practices [50, 51].
Although this is a step toward remediation of systems-
level practice barriers to improve quality of care, our re-
sults suggest that both PCPs and neurology specialists
need more training and support in neurocognitive assess-
ment methods and the choice of neuroimaging modalities
in the evaluation of NCD patients.
Limitations
The generalizability of this study is limited by the small
sample size and bias due to participants self-selecting to re-
spond to the survey. Additionally, PCP respondents work in
many different practice environments (e.g. higher percent-
age of patients over 55, social worker/nurse practitioner/
care manager on premises, socioeconomic status of popula-
tion served), which may have differentially impacted their
approach to dementia assessment and care. The small sam-
ple size limited our ability to determine the impact of these
potentially confounding factors. Another important limita-
tion is that self-perceived confidence is an imperfect proxy
for actual effectiveness. For example, providers may indicate
confidence in an area despite never actually implementing
that practice, or they may be over-confident in their abilities
but be very ineffective in practice. There may also be sam-
pling bias because we offered payment for the completion
of our survey. However, payment was minimal, and was ac-
cepted by our IRB as an amount that would not be consid-
ered coercive. Additionally, we did not pilot the survey prior
to dissemination. Finally, while the practice characteristics
of primary care providers surveyed in our study were mostly
comparable to other large studies, our study had more pro-
viders reporting working in private practice [52].
Conclusions
By 2050 more than 131 million people around the world
will have dementia, and the prevalence of undetected de-
mentia is high across the globe [53]. The current global
costs of dementia are US $818 billion, which is expected to
grow [54]. While our study focused on providers in the
United States, to our knowledge there are no studies in glo-
bal settings about provider confidence, attitudes, and prac-
tices in regards to specific aspects of the dementia
evaluation performed. More work is thus needed to identify
whether the issues described here are seen globally. This
study illuminates a number of underlying causes for PCP’s
lack of comfort and knowledge in the diagnosis and man-
agement of their patients with NCDs in the United States
setting. These practice gaps were identified in several areas
including cognitive testing, neuroimaging, and the know-
ledge of published diagnostic criteria for distinct NCD syn-
dromes. Educational and practice-based interventions can
remedy these gaps quickly. There is hope that such changes
can realistically be achieved, given that PCPs are generally
open to improvement and are eager to gain additional sup-
port guiding the decision processes around the identifica-
tion, diagnosis, and care of their patients with NCDs.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12913-019-4603-2.
Additional file 1. Provider Survey.
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